Abstract: Disclosed are nucleotide sequences, for example, DNA or RNA sequences, which encode an immunoglobulin Fc-Leptin fusion protein. The nucleotide sequences can be inserted into a suitable expression vector and expressed in mammalian cells. Also disclosed is a family of immunoglobulin Fc-Leptin fusion proteins that can be produced by expression of such nucleotide sequences. Also disclosed are methods using such nucleotide sequences and fusion proteins for treating conditions which are alleviated by the administration of leptin.
Type:
Application
Filed:
April 18, 2003
Publication date:
March 18, 2004
Applicant:
Lexigen Pharmaceuticals Corp.
Inventors:
Kin-Ming Lo, Jinyang Zhang, Stephen D. Gillies
Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.
Type:
Application
Filed:
March 29, 2002
Publication date:
September 4, 2003
Applicant:
Lexigen Pharmaceuticals Corp.
Inventors:
Stephen D. Gillies, Jeffrey Way, Anita A. Hamilton
Abstract: The invention provides a family of antibodies that specifically bind the human epithelial cell adhesion molecule. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies, when coupled to the appropriate moiety, may be used in the diagnosis, prognosis and treatment of cancer.
Type:
Application
Filed:
May 3, 2002
Publication date:
August 21, 2003
Applicant:
Lexigen Pharmaceuticals Corp.
Inventors:
Stephen D. Gillies, Kin-Ming Lo, Susan X. Qian
Abstract: Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.
Type:
Application
Filed:
March 7, 2002
Publication date:
March 6, 2003
Applicant:
Lexigen Pharmaceuticals Corp.
Inventors:
Stephen D. Gillies, Jeffrey Way, King-Ming Lo